Posted by jrbecker76 on February 12, 2009, at 21:52:44
This AP is due to be reviewed by the FDA in late Spring. As some might recall, this drug was pulled from the EU market after its brief introduction in 1998 due to some concerns over heart arrhythmia. Sertindole has since been re-approved in in the EU and Mexico.
Its pharmacology is as a D2 antagonist/5-HT2 antagonist/alpha1&alpha2 adrenergic antagonist. Reports suggest negligible EPS, minor weight gain, sedation; has pro-cognitive effects and might have an impact on negative symptoms.
It be interesting to align these claims with any subjective feedback from experienced users.
JB
poster:jrbecker76
thread:879789
URL: http://www.dr-bob.org/babble/20090203/msgs/879789.html